- Home
- IMTX vs ABCL Comparison
IMTX vs ABCL Comparison
Compare IMTX & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMTX | ABCL |
|---|---|---|
| Founded | N/A | 2012 |
| Country | Germany | Canada |
| Employees | 407 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.6B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | IMTX | ABCL |
|---|---|---|
| Price | $9.32 | $5.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | ★ $19.00 | $8.40 |
| AVG Volume (30 Days) | 325.4K | ★ 6.8M |
| Earning Date | 05-13-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.91 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $75,128,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $25.91 | $21.85 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 160.56 |
| 52 Week Low | $5.05 | $2.75 |
| 52 Week High | $12.41 | $8.44 |
Technical Indicators
Market Signals| Indicator | IMTX | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 38.72 | 41.92 |
| Support Level | $8.99 | $5.23 |
| Resistance Level | $10.67 | $6.79 |
| Average True Range (ATR) | 0.44 | 0.55 |
| MACD | -0.04 | -0.24 |
| Stochastic Oscillator | 0.00 | 5.86 |
Price Performance
Historical ComparisonAbout IMTX Immatics N.V.
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
About ABCL AbCellera Biologics Inc.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.